Pfizer and Atomwise Signs an Evaluation Agreement to Identify Potential Drug for Target Proteins Using AI Technology

 Pfizer and Atomwise Signs an Evaluation Agreement to Identify Potential Drug for Target Proteins Using AI Technology

Pfizer and Atomwise Signs an Evaluation Agreement to Identify Potential Drug for Target Proteins Using AI Technology

Shots:

  • Pfizer will pay access fee for using Atomwise’s AI technology with success-based payments for each target protein selected, while Atomwise will computationally analyse various small molecules for each of Pfizer’s identified target proteins
  • Additionally, Atomwise medicinal and computational chemistry team will work collaboratively with Pfizer scientists to identify potency and chemical properties of the small molecules
  • Atomwise’s platform is based on AI technology to extract statistical insights from experimental affinity measurements and protein structures to predict the binding of small molecules to proteins

Click here to read full press release/ article | Ref: Atomwise | Image: WuxiMediaGlobal

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post